Media Mentions9.8.24
A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets

Taylor Wirth was quoted in a MedCity News article, "A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets," regarding the difference between an IPO and a direct listing and why a biotech company might choose one over the other.
Keep Up to Date in a Changing World
Do you want to receive more valuable insights directly in your inbox? Visit our subscription center and let us know what you’re interested in learning more about.
